MM4TB logo
News

Future events 2016 2015 2014 2013 2012 2011






Professor Gyorgy Keri PhD, DSc
CEO & CSO of Vichem Chemie Research Ltd


Lausanne, 22 July 2016

The members of the MM4TB consortium were saddened to hear that Professor Gyorgy Keri of ViChem had passed away. Gyorgy was unable to attend our Bratislava meeting because of poor health. Gyorgy led the ViChem team in the New Medicines for Tuberculosis (NM4TB) and More Medicines for Tuberculosis (MM4TB) projects for over 10 years. Gyorgy was an excellent person to deal with and his company made a fantastic contribution to NM4TB & MM4TB thanks to the hard work by all concerned and especially due to Gyorgy's positive, open and friendly attitude. We were very grateful when he offered to host the second NM4TB meeting in Budapest, and then two years ago a meeting for MM4TB, despite knowing just how much hard work was involved.

In the words of one consortium member: 'He always saw the person and not just the project or the achievements. He loved to be together with young people, he was very dynamic and always full of optimism. He could transfer to the others his strong belief in making the world better and looking forward to new challenges. ... He adored kids and he participated in a lots of charity events to support poor or orphan kids. I considered Vichem as a family more than a company. It is sad that he had to die of a disease against which he was always fighting in research.'

Gyorgy will be sadly missed and the thoughts of all MM4TB members are with his family at this sad time.

Gyorgy's final commemoration after his cremation will be organized the 4th of August, 9:45 am in the Farkasréti Cemetery, Budapest.

In case of attendance, the family asked to take only one flower (not a big wreath). The money one would spend for the wreath could be donated to the Saint Francis Foundation of Deva in memory of Gyorgy. This is a Foundation which takes care of orphan kids and Gyorgy was involved in a lots of its activities.

Curriculum vitae

Gyorgy Keri was a founder of Vichem Chemie Research Ltd; his position was Chief Executive Officer and Chief Scientific Officer. He was a Professor and Head of the Pathobiochemistry Research Group of the Hungarian Academy of Sciences at Semmelweis University, and the President of Rational Drug Design Laboratories Cooperation Research Center. Gyorgy Keri was a chemist by profession and got his PhD in biochemistry in 1976 at Eotvos University of Sciences, Budapest, and was a post doc in 1978-1979 with Prof. J. Ramachandran, University of California, San Francisco. He was a Visiting Scientist in the United States 19 times for various time periods on the bases of joint research programs with UCSF, Genentech and SUgen. He founded Biosignal Ltd in 1992 to utilize and develop his signal-inhibiting somatostatin peptide compound (TT-232) which had reached Phase II clinical trials and was licensed to Tallion Pharmaceuticals. He has been collaborating with Prof. Axel Ullrich (chief scientist of Genentech, Max Planck Institute and Sugen) for more than 25 years on developing kinase inhibitors. He was advisor and collaborative partner of Sugen between 1992 and 1999 and Axxima Pharmaceuticals between 1999 and 2005. He was involved in the development of SU-101, which has reached Phase III clinical trial at Sugen. He developed the Nested Chemical Library technology at Biosignal and later on at Vichem. He has also participated in the development of the KinaTor technology for selectivity profiling of kinase inhibitors. He has participated in the development of four developmental candidate compounds against oncological and infectious disease targets which were sublicenced. He has participated in several EU grants and was the coordinator of one grant. Gyorgy Keri has received 2 international and 8 Hungarian awards, published 179 scientific papers in international journals, and has 101 international patents. He was co-Editor in Chief of the journal, Signal Transduction Therapy, and co-Editor of the book, Molecular pathomechanisms, new trends in drug research (Taylor & Francis). He was member of the Executive Committee of the Hungarian Biotech Association and of EuropaBio.


Gyorgy Keri
Professor Gyorgy Keri PhD, DSc
CEO & CSO of Vichem Chemie Research Ltd


MM4TB Budapest
MM4TB researchers at Budapest, Hungary, July 2014, meeting hosted by Gyorgy Keri




Eleventh MM4TB Consortium Meeting

Bratislava, Slovakia, 27 - 28 June 2016

The twelfth and final Consortium Meeting (CM12) was hosted by Dr Katarina Mikusova of the University of Bratislava at the Hotel Devin in Bratislava, Slovakia on 27 - 28 June 2016.

There were 38 registered participants. All beneficiaries were represented by at least one person with the exception of IISC (presentation made by Tony Maxwell of JIC on their behalf), Cellworks UPV/EHU, Alere & UCT.

As no member of the Scientific Advisory Board was present at the meeting, the prizes for best presentations by young researchers were presented by Prof. Anthony Maxwell of the John Innes Institute to Jaroslav Roh (Charles University), Beatrice Orena (UNIPV) and Mohamad Sabbah (UCAM).

The Barry Furr Lecture was entitled 'Repurposing clinically approved cephalosporins for tuberculosis therapy' and was presented by Dr Santiago Ramon-Garcia of the University of British Columbia.

A presentation was also made, by Prof. Roland Brosch, Institut Pasteur, on behalf of all participants, to Prof. Stewart Cole, FRS of EPFL in appreciaton for his excellent leadership of X-TB (FP5), NM4TB (FP6) & MM4TB (FP7).


NM4TB Bratislava
New Medicines for Tuberculosis (NM4TB) Scientific Meeting
Kamila Hotel, Bratislava, Slovakia 22 - 23 May 2006


Bratislava
More Medicines for Tuberculosis (MM4TB) Scientific Meeting
Hotel Devin, Bratislava, Slovakia 27 - 28 June 2016




Eleventh MM4TB Consortium Meeting

Pavia, Italy, 11 - 12 January 2016

The eleventh Consortium Meeting (CM11) was hosted by Prof. Giovanna Riccardi at the University of Pavia in Pavia, Italy on 11 - 12 January 2016.

There were 52 registered participants. All beneficiaries were represented by at least one person with the exception of Cellworks and Alere.

Dr Hannu Laang of the European Commission and the Project's Scientific Officer was also present at the meeting and participated in the discussions, including those concerning the six month no-cost extension for the project.

The Barry Furr Lecture was entitled 'New medicines for Burkholderia cenocepacia: a neglected infection in Cystic Fibrosis patients' and was presented by Dr Silvia Buroni of UNIPV.

As no member of the Scientific Advisory Board was present at the meeting, Dr Sean Ekins, Chief Scientific Officer of Collaborative Drug Development (CDD) presented the awards.

The prizes for best presentations by young researchers were won by Mariline Dong (ETHZ), Mohamad Sabbath (UCAM) and Marta Esposito (UNIPV).

The twelfth Consortium Meeting (CM11) will hosted by Dr Katarina Mikusova at Bratislava, Slovakia on 27 - 28 January 2016.



Charity stamp
Postcard with Italian Tuberculosis charity stamp